Bisphosphonate therapy for osteoporosis: Benefits, risks, and drug holiday

American Journal of Medicine

Volumn 126, Issue 1, 2013, Pages 13-20

  McClung, Michael ^a   Harris, Steven T ^b   Miller, Paul D ^c   Bauer, Douglas C ^b   Davison, K Shawn ^d   Dian, Larry ^e   Hanley, David A ^f   Kendler, David L ^e   Yuen, Chui Kin ^g   Lewiecki, E Michael ^h  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Colorado Center for Bone Research ^*  (Australia)

^d UNIVERSITY OF VICTORIA   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g Manitoba Clinic   (Canada)

^h Osteoporosis Center   (United States)

Author keywords

Adverse events; Bisphosphonates; Drug holiday; Fracture

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID; IBANDRONIC ACID; PROTON PUMP INHIBITOR; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; CANCER CHEMOTHERAPY; ESOPHAGUS CANCER; EYE DISEASE; FEMUR FRACTURE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOSPITALIZATION; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; KIDNEY FAILURE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SPINE FRACTURE;

ATRIAL FIBRILLATION; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESOPHAGEAL NEOPLASMS; FEMORAL FRACTURES; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT;

EID: 84871623655     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2012.06.023     Document Type: Review

References (85)

1. R.G. Russell, N.B. Watts, F.H. Ebetino, M.J. Rogers Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int 19 2008 733 759
2. C. MacLean, S. Newberry, M. Maglione Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 2008 197 213
3. E.S. Siris, M.K. Pasquale, Y. Wang, N.B. Watts Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001-2008 J Bone Miner Res 26 2011 3 11
4. D.M. Black, S.R. Cummings, D.B. Karpf Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
5. S.R. Cummings, D.M. Black, D.E. Thompson Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082
6. S.T. Harris, N.B. Watts, H.K. Genant Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352
7. J. Reginster, H.W. Minne, O.H. Sorensen Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 2000 83 91
8. M.R. McClung, P. Geusens, P.D. Miller Effect of risedronate on the risk of hip fracture in elderly women Hip Intervention Program Study Group N Engl J Med 344 2001 333 340
9. D.M. Black, P.D. Delmas, R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809 1822
10. K.W. Lyles, C.S. Colon-Emeric, J.S. Magaziner Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 357 2007 1799 1809
11. K.E. Ensrud, E.L. Barrett-Connor, A. Schwartz Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension J Bone Miner Res 19 2004 1259 1269
12. D.M. Black, A.V. Schwartz, K.E. Ensrud Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2006 2927 2938
13. D.D. Mellstrom, O.H. Sorensen, S. Goemaere, C. Roux, T.D. Johnson, A.A. Chines Seven years of treatment with risedronate in women with postmenopausal osteoporosis Calcif Tissue Int 75 2004 462 468
14. H.G. Bone, D. Hosking, J.P. Devogelaer Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 2004 1189 1199
15. C.H. Chesnut III, A. Skag, C. Christiansen Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 2004 1241 1249
16. Z. Wang, T. Bhattacharyya Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007 J Bone Miner Res 26 2011 553 560
17. E. Orwoll, M. Ettinger, S. Weiss Alendronate for the treatment of osteoporosis in men N Engl J Med 343 2000 604 610
18. S. Wallach, S. Cohen, D.M. Reid Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy Calcif Tissue Int 67 2000 277 285
19. M.C. Nevitt, D.E. Thompson, D.M. Black Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures Fracture Intervention Trial Research Group Arch Intern Med 160 2000 77 85
20. J.R. Center, D. Bliuc, N.D. Nguyen, T.V. Nguyen, J.A. Eisman Osteoporosis medication and reduced mortality risk in elderly women and men J Clin Endocrinol Metab 96 2011 1006 1014
21. P.N. Sambrook, I.D. Cameron, J.S. Chen Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study Osteoporos Int 22 2011 2551 2556
22. R. Dell, D. Greene Is osteoporosis disease management cost effective? Curr Osteoporos Rep 8 2010 49 55
23. E.D. Newman, W.T. Ayoub, R.H. Starkey, J.M. Diehl, G.C. Wood Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years Osteoporos Int 14 2003 146 151
24. L.A. Beaupre, D.W. Morrish, D.A. Hanley Oral bisphosphonates are associated with reduced mortality after hip fracture Osteoporos Int 22 2011 983 991
25. M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid Effect of osteoporosis treatment on mortality: a meta-analysis J Clin Endocrinol Metab 95 2010 1174 1181
26. U.S. Food and Drug Administration What is a serious adverse event? http://www.fda. gov/safety/medwatch/howtoreport/ucm053087.htm Accessed October 31, 2011
27. R. Dowd, R.R. Recker, R.P. Heaney Study subjects and ordinary patients Osteoporos Int 11 2000 533 536
28. S. Khosla, D. Burr, J. Cauley Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491
29. C.A. Migliorati, M.M. Schubert, D.E. Peterson, L.M. Seneda Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy Cancer 104 2005 83 93
30. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg, S.L. Engroff Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 2004 527 534
31. A.P. Sarathy, S.L. Bourgeois Jr, G.G. Goodell Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports J Endod 31 2005 759 763
32. K.B. Olson, C.M. Hellie, K.J. Pienta Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid Urology 66 2005 658
33. V.M. Cartsos, S. Zhu, A.I. Zavras Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people J Am Dent Assoc 139 2008 23 30
34. J.C. Lo, F.S. O'Ryan, N.P. Gordon Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure J Oral Maxillofac Surg 68 2010 243 253
35. T. Mavrokokki, A. Cheng, B. Stein, A. Goss Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia J Oral Maxillofac Surg 65 2007 415 423
36. J.W. Hellstein, R.A. Adler, B. Edwards Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs J Am Dent Assoc 142 2011 1243 1251
37. R.E. Marx, J.E. Cillo Jr, J.J. Ulloa Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment J Oral Maxillofac Surg 65 2007 2397 2410
38. E. Shane, D. Burr, P.R. Ebeling Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2010 2267 2294
39. A. Giusti, N.A. Hamdy, S.E. Papapoulos Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies Bone 47 2 2010 169 180
40. J. Schilcher, K. Michaelsson, P. Aspenberg Bisphosphonate use and atypical fractures of the femoral shaft N Engl J Med 364 2011 1728 1737
41. A. Feldstein, D. Black, N. Perrin Incidence and demography of femur fractures with and without atypical features J Bone Miner Res 27 5 2012 977 986
42. D.A. Kumm, C. Rack, J. Rutt Subtrochanteric stress fracture of the femur following total knee arthroplasty J Arthroplasty 12 1997 580 583
43. R. Niimi, M. Hasegawa, A. Sudo, A. Uchida Unilateral stress fracture of the femoral shaft combined with contralateral insufficiency fracture of the femoral shaft after bilateral total knee arthroplasty J Orthop Sci 13 2008 572 575
44. B.A. Lenart, A.S. Neviaser, S. Lyman Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study Osteoporos Int 20 2009 1353 1362
45. J. Schilcher, P. Aspenberg Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate Acta Orthop 80 2009 413 415
46. A. Giusti, N.A. Hamdy, O.M. Dekkers, S.R. Ramautar, S. Dijkstra, S.E. Papapoulos Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features Bone 48 2011 966 971
47. R.M. Dell, A.L. Adams, D.F. Greene et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur J Bone Miner Res 2012 Jul 26 10.1002/jbmr.1719 [Epub ahead of print]
48. S.R. Cummings, A.V. Schwartz, D.M. Black Alendronate and atrial fibrillation N Engl J Med 356 2007 1895 1896
49. R. Karam, J. Camm, M. McClung Yearly zoledronic acid in postmenopausal osteoporosis N Engl J Med 357 2007 712 713
50. E.M. Lewiecki, C. Cooper, E. Thompson, F. Hartl, D. Mehta, S.E. Papapoulos Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials Int J Clin Pract 64 2010 821 826
51. U.S. Food and Drug Administration Update of safety review follow-up to the October 1, 2007 Early communication about the ongoing safety review of bisphosphonates http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm136201 Accessed August 11, 2011
52. D.K. Wysowski Reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 2009 89 90
53. J. Green, G. Czanner, G. Reeves, J. Watson, L. Wise, V. Beral Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort BMJ 341 2010 c4444
54. B. Abrahamsen, P. Eiken, R. Eastell More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 2009 1789 author reply 1791-1792
55. D.H. Solomon, A. Patrick, M.A. Brookhart More on reports of esophageal cancer with oral bisphosphonate use N Engl J Med 360 2009 1789 1790
56. C.R. Cardwell, C.C. Abnet, M.M. Cantwell, L.J. Murray Exposure to oral bisphosphonates and risk of esophageal cancer JAMA 304 2010 August 11 657 663
57. U.S. Food and Drug Administration FDA drug safety communication: ongoing safety review of oral osteoporosis drugs (bisphosphonates) and potential increased risk of esophageal cancer http://www.fda.gov/Drugs/DrugSafety/ ucm263320.htm Accessed January 12, 2012
58. B. Cryer, D.C. Bauer Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77 2002 1031 1043
59. S. Greenspan, E. Field-Munves, R. Tonino Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study Mayo Clin Proc 77 2002 1044 1052
60. P.D. Miller, S. Epstein, F. Sedarati, J.Y. Reginster Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study Curr Med Res Opin 24 2008 207 213
61. S.T. Harris, J.Y. Reginster, C. Harley Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study Bone 44 2009 758 765
62. P.C. de Groen, D.F. Lubbe, L.J. Hirsch Esophagitis associated with the use of alendronate N Engl J Med 335 1996 1016 1021
63. W. Strampel, R. Emkey, R. Civitelli Safety considerations with bisphosphonates for the treatment of osteoporosis Drug Saf 30 2007 755 763
64. S.M. Cadarette, J.N. Katz, M.A. Brookhart Comparative gastrointestinal safety of weekly oral bisphosphonates Osteoporos Int 20 2009 1735 1747
65. J.J. Body, T. Pfister, F. Bauss Preclinical perspectives on bisphosphonate renal safety Oncologist 10 Suppl 1 2005 3 7
66. G.S. Markowitz, P.L. Fine, J.I. Stack Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 2003 281 289
67. US Food and Drug Administration FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid) http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm Accessed February 9, 2012
68. P.D. Miller, M.R. McClung, L. Macovei Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res 20 2005 1315 1322
69. O. Bock, H. Boerst, F.E. Thomasius Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention J Musculoskelet Neuronal Interact 7 2007 144 148
70. P.D. Delmas, S. Adami, C. Strugala Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study Arthritis Rheum 54 2006 1838 1846
71. I.R. Reid, G.D. Gamble, P. Mesenbrink, P. Lakatos, D.M. Black Characterization of and risk factors for the acute-phase response after zoledronic acid J Clin Endocrinol Metab 95 2010 4380 4387
72. C.H. Chesnut III, M.R. McClung, K.E. Ensrud Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling Am J Med 99 1995 144 152
73. S.E. Papapoulos, H.I. Harinck, O.L. Bijvoet, J.H. Gleed, L.J. Fraher, J.L. O'Riordan Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD Bone Miner 1 1986 69 78
74. N.S. Sharma, J.L. Ooi, K. Masselos, M.J. Hooper, I.C. Francis Zoledronic acid infusion and orbital inflammatory disease N Engl J Med 359 2008 1410 1411
75. F.W. Fraunfelder Ocular side effects associated with bisphosphonates Drugs Today (Barc) 39 2003 829 835
76. S.L. Bonnick Going on a drug holiday? J Clin Densitom 14 2011 377 383
77. D.M. Black, I.R. Reid, S. Boonen The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J Bone Miner Res 27 2 2012 243 254
78. N.B. Watts, A. Chines, W.P. Olszynski Fracture risk remains reduced one year after discontinuation of risedronate Osteoporos Int 19 2008 365 372
79. A.V. Schwartz, D.C. Bauer, S.R. Cummings Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial J Bone Miner Res 25 2010 976 982
80. J.R. Curtis, A.O. Westfall, H. Cheng, E. Delzell, K.G. Saag Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday Osteoporos Int 19 2008 1613 1620
81. A.M. Gallagher, S. Rietbrock, M. Olson, T.P. van Staa Fracture outcomes related to persistence and compliance with oral bisphosphonates J Bone Miner Res 23 2008 1569 1575
82. M. Whitaker, J. Guo, T. Kehoe, G. Benson Bisphosphonates for osteoporosis - where do we go from here? N Engl J Med 366 22 2012 2048 2051
83. S.L. Bonnick, L. Shulman Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 119 2006 S25 S31
84. J.A. Kanis, E.V. McCloskey, H. Johansson, A. Oden, O. Strom, F. Borgstrom Development and use of FRAX in osteoporosis Osteoporos Int 21 Suppl 2 2010 S407 S413
85. W.D. Leslie, C. Berger, L. Langsetmo Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts Osteoporos Int 22 6 2011 1873 1883